IL184371A - Use of an anti il-31ra antibody in the manufacture of a medicament for treating skin disorders - Google Patents

Use of an anti il-31ra antibody in the manufacture of a medicament for treating skin disorders

Info

Publication number
IL184371A
IL184371A IL184371A IL18437107A IL184371A IL 184371 A IL184371 A IL 184371A IL 184371 A IL184371 A IL 184371A IL 18437107 A IL18437107 A IL 18437107A IL 184371 A IL184371 A IL 184371A
Authority
IL
Israel
Prior art keywords
medicament
antibody
manufacture
skin disorders
treating skin
Prior art date
Application number
IL184371A
Other languages
English (en)
Other versions
IL184371A0 (en
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of IL184371A0 publication Critical patent/IL184371A0/en
Publication of IL184371A publication Critical patent/IL184371A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL184371A 2005-02-14 2007-07-03 Use of an anti il-31ra antibody in the manufacture of a medicament for treating skin disorders IL184371A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65328305P 2005-02-14 2005-02-14
US69486705P 2005-06-29 2005-06-29
US71676105P 2005-09-13 2005-09-13
PCT/US2006/005148 WO2006088855A1 (en) 2005-02-14 2006-02-14 Methods of treating skin disorders using an il-31ra antagonist

Publications (2)

Publication Number Publication Date
IL184371A0 IL184371A0 (en) 2007-10-31
IL184371A true IL184371A (en) 2010-12-30

Family

ID=36572470

Family Applications (2)

Application Number Title Priority Date Filing Date
IL184371A IL184371A (en) 2005-02-14 2007-07-03 Use of an anti il-31ra antibody in the manufacture of a medicament for treating skin disorders
IL207688A IL207688A0 (en) 2005-02-14 2010-08-19 Methods of treating skin disorders using an il-31ra antagonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL207688A IL207688A0 (en) 2005-02-14 2010-08-19 Methods of treating skin disorders using an il-31ra antagonist

Country Status (8)

Country Link
US (9) US20060182743A1 (cg-RX-API-DMAC10.html)
EP (1) EP1858924A1 (cg-RX-API-DMAC10.html)
JP (1) JP2008530132A (cg-RX-API-DMAC10.html)
AU (1) AU2006214404B2 (cg-RX-API-DMAC10.html)
CA (1) CA2594490A1 (cg-RX-API-DMAC10.html)
IL (2) IL184371A (cg-RX-API-DMAC10.html)
MX (1) MX2007009718A (cg-RX-API-DMAC10.html)
WO (1) WO2006088855A1 (cg-RX-API-DMAC10.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1188830T3 (da) * 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
EP1221482B1 (en) 1999-09-27 2005-12-28 Chugai Seiyaku Kabushiki Kaisha Hemopoietin receptor protein, nr12
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
WO2004003140A2 (en) * 2002-01-18 2004-01-08 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
US9738700B2 (en) 2002-01-18 2017-08-22 Zymogenetics Inc. ZCYTOR17 heterodimeric cytokine receptor
RU2490276C2 (ru) 2002-01-18 2013-08-20 Займоджинетикс, Инк. Новый лиганд рецептора цитокина zcytor17
EP1858924A1 (en) * 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
JP4927762B2 (ja) 2005-02-14 2012-05-09 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法
US8101183B2 (en) * 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
CN101198624B (zh) * 2005-05-06 2012-10-10 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
EP2001906A2 (en) 2006-01-10 2008-12-17 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
ES2544888T3 (es) * 2006-06-08 2015-09-04 Chugai Seiyaku Kabushiki Kaisha Prevención o remedio para enfermedades inflamatorias
EP2061811A2 (en) 2006-09-01 2009-05-27 ZymoGenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
AU2008204823A1 (en) 2007-01-10 2008-07-17 Zymogenetics, Inc Methods of using IL-31 to treat airway hyper-responsiveness and asthma
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
CA2708065C (en) * 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
TWI548418B (zh) * 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
SI2796466T1 (en) 2007-12-07 2018-01-31 Zymogenetics, Inc. Molecules of Humanized Specifics Specifiable for IL-31
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
JP5139517B2 (ja) * 2008-12-05 2013-02-06 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2014176696A1 (en) * 2013-04-30 2014-11-06 Université de Montréal Novel biomarkers for acute myeloid leukemia
HUE056580T2 (hu) 2013-05-30 2022-02-28 Kiniksa Pharmaceuticals Ltd Onkosztatin-M-receptor antigénjét kötõ fehérjék
TW201537175A (zh) * 2013-06-28 2015-10-01 Chugai Pharmaceutical Co Ltd 預測罹患具皮膚搔癢之疾病的患者對ｉｌ－３１拮抗劑之治療的反應之方法
FI3284480T3 (fi) 2015-04-14 2025-09-11 Chugai Pharmaceutical Co Ltd IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi
US10946078B2 (en) * 2016-04-27 2021-03-16 Benchmark Animal Health Ltd. Treatment of canine atopic dermatitis
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
PL3749353T3 (pl) * 2018-02-09 2025-12-08 Galderma Holding SA Nemolizumab w leczeniu atopowego zapalenia skóry z przeczosami o nasileniu od umiarkowanego do ciężkiego
CA3093709C (en) 2018-03-16 2024-03-26 Zoetis Services Llc Peptide vaccines against interleukin-31
JP7449234B2 (ja) 2018-03-16 2024-03-13 ゾエティス・サービシーズ・エルエルシー 獣医学使用のためのインターロイキン３１モノクローナル抗体
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
KR20210079278A (ko) * 2018-09-06 2021-06-29 시다라 세라퓨틱스, 인코포레이티드 바이러스 감염의 치료를 위한 조성물 및 방법
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体
WO2021100794A1 (ja) 2019-11-20 2021-05-27 中外製薬株式会社 抗体含有製剤
WO2021123092A1 (en) 2019-12-20 2021-06-24 Intervet International B.V. Bispecific caninized antibodies for treating atopic dermatitis
CA3189847A1 (en) 2020-09-01 2022-03-10 Naoki Fukazawa Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
TW202607038A (zh) 2020-10-19 2026-02-16 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途
WO2025167991A1 (zh) * 2024-02-07 2025-08-14 武汉人福创新药物研发中心有限公司 一种靶向il-31ra的抗体或其抗原结合片段及其应用
WO2026032397A1 (en) * 2024-08-09 2026-02-12 Zai Lab (Shanghai) Co., Ltd. Binding molecules with an interleukin-31 receptor subunit alpha-antigen-binding domain and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK1188830T3 (da) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
EP2075253A1 (en) 2000-06-23 2009-07-01 Genentech, Inc. Compositions and methds for the diagnosis and treatment of disorders involving angiogensis
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
EP1325115B1 (en) * 2000-06-26 2016-07-27 ZymoGenetics, Inc. Cytokine receptor zcytor17
US20030059871A1 (en) 2000-10-06 2003-03-27 Cosman David J. Hematopoietin receptors HPR1 and HPR2
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
RU2490276C2 (ru) 2002-01-18 2013-08-20 Займоджинетикс, Инк. Новый лиганд рецептора цитокина zcytor17
WO2004003140A2 (en) * 2002-01-18 2004-01-08 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
US7303896B2 (en) 2002-02-25 2007-12-04 Genentech, Inc. Nucleic acid encoding novel type-1 cytokine receptor GLM-R
JP4927762B2 (ja) 2005-02-14 2012-05-09 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法
EP1858924A1 (en) 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
CN101198624B (zh) 2005-05-06 2012-10-10 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
EP2001906A2 (en) 2006-01-10 2008-12-17 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
EP2061811A2 (en) 2006-09-01 2009-05-27 ZymoGenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use

Also Published As

Publication number Publication date
US7871618B2 (en) 2011-01-18
US20180244790A1 (en) 2018-08-30
US20110117052A1 (en) 2011-05-19
US20170137525A1 (en) 2017-05-18
WO2006088855A1 (en) 2006-08-24
JP2008530132A (ja) 2008-08-07
US20170275369A1 (en) 2017-09-28
AU2006214404A1 (en) 2006-08-24
US11312779B2 (en) 2022-04-26
US20200239581A1 (en) 2020-07-30
IL207688A0 (en) 2010-12-30
US20180094068A1 (en) 2018-04-05
US10611846B2 (en) 2020-04-07
IL184371A0 (en) 2007-10-31
US20150344581A1 (en) 2015-12-03
US20090252730A1 (en) 2009-10-08
US20060182743A1 (en) 2006-08-17
AU2006214404B2 (en) 2012-03-08
MX2007009718A (es) 2007-09-26
CA2594490A1 (en) 2006-08-24
US9139651B2 (en) 2015-09-22
EP1858924A1 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
ZA200702130B (en) Memantine for the treatment of childhood behavioral disorders
SI1976886T1 (sl) Sredstva in postopki za zdravljenje tumorskih bolezni
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL197169A0 (en) Use of fgf-18 in the manufacture of a medicament for treatment of cartilage disorders
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
PT2056842E (pt) Galactosil-ceramidas modificadas para coloração e estimulação de células t assassinas naturais
IL193747A0 (en) New therapeutic combinations for the treatment of depression
PL1919450T3 (pl) Kompozycja liposomowa zawierająca lek przeciwhistaminowy i kortykosteroid oraz jej zastosowanie do wytwarzania leku do leczenia nieżytu nosa i chorób spokrewnionych
IL188390A0 (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
EP2094281A4 (en) USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES OR OCULAR DISORDERS
PL2101731T3 (pl) Endoksyfen do zastosowania w leczeniu nowotworu
IL182407A (en) Use of agomalatine for a drug designed to treat general anxiety disorders
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
ZA200806095B (en) Means and methods for the treatment of tumorous diseases
ZA200810199B (en) Rinse-off therapeutic agents for treating skin
EP2005964A4 (en) MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
GB2427361B (en) Treatment device for the human body
GB0523961D0 (en) The treatment of ophthalmic diseases
BRPI0714307A2 (pt) Uso de benzamidas trifluormetil-substituídas no tratamento de distúrbios neurológicos
EP2059238A4 (en) THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS
PL1714647T3 (pl) Zastosowanie agomelatyny do wytwarzania leku do leczenia zaburzeń dwubiegunowych
IL193944A0 (en) The use beta-aminoalcohols for the treatment of inflammatory disorders and pain
GB0523964D0 (en) The treatment of ophthalmic diseases

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees